Pathologic features, proliferative activity, and cyclin D1 expression in Hurthle cell neoplasms of the thyroid

Modern Pathology

Volumn 13, Issue 2, 2000, Pages 186-192

  Erickson, Lori A ^a   Jin, Long ^a   Goellner, John R ^a   Lohse, Christine ^a   Pankratz, V Shane ^a   Zukerberg, Lawrence R ^b   Thompson, Geoffrey B ^a   Van Heerden, Jon A ^a   Grant, Clive S ^a   Lloyd, Ricardo V ^a,c  

^a MAYO CLINIC   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Laboratory Medicine and Pathology   (United States)

Author keywords

Cyclin D1; Hurthle cell; Ki67; Thyroid

Indexed keywords

CYCLIN D1; KI 67 ANTIGEN; MONOCLONAL ANTIBODY KI 67;

ADULT; ARTICLE; CANCER INVASION; CANCER SIZE; CELL CYCLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ONCOCYTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID ADENOMA; THYROID CARCINOMA; THYROID PARAFOLLICULAR CELL;

EID: 0033955743     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3880034     Document Type: Article

References (37)

1. Watson RG, Brennan MD, Goellner JR, van Heerden JA, McConahey WM, Taylor WF. Invasive Hurthle cell carcinoma of the thyroid: natural history and management. Mayo Clin Proc 1984;59:851-5.
2. Carr K, Heffess C, Jin L, Lloyd RV. Immunohistochemical analysis of thyroid carcinomas utilizing antibodies to p53 and Ki67. Appl Immunohistochem 1993;1:201-7.
3. Pelosi G, Zamburi G. Proliferation markers and their uses in the study of endocrine tumors. Endocr Pathol 1996;7:103-19.
4. Erickson LA, Jin L, Wollan PC, Thompson GB, van Heerden J, Lloyd RV. Expression of p27kipl and Ki67 in benign and malignant thyroid tumors. Mod Pathol 1998;11:169-74.
5. Zou M, Shi Y, Farid NR, Al-Sedairy ST. Inverse association between cyclin D1 overexpression and retinoblastoma gene mutation in thyroid carcinomas. Endocrine 1998;8:61-4.
6. Lazzereschi D, Sambuco L, Scalzo CC, Ranieri AR, Mincione G, Nardi F, et al. Cyclin D1 and cyclin E expression in malignant thyroid cells and in human thyroid carcinomas. Int J Cancer 1998;76:806-11.
7. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki67. J Immunol 1984;133:1710-5.
8. Matsushime H, Roussel MF, Ashmun RA, Sherr CJ. Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell 1991;65:701-13.
9. Won KA, Xiong Y, Beach D, Gilman MZ. Growth-regulated expression of D-type cyclin genes in human diploid fibroblasts. Proc Natl Acad Sci U S A 1992;89:9910-4.
10. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 1993;7:812-21.
11. Lukas J, Pagano M, Staskova Z, Draetta G, Bartek J. Cyclin D1 protein oscillates and is essential for cell cycle progression in human tumour cell lines. Oncogene 1994;9:707-18.
12. Motokura T, Bloom T, Kim HG, Juppner H, Ruderman JV, Kronenberg HM, et al. A novel cyclin encoded by a bcl-linked candidate oncogene. Nature 1991;350:512-5.
13. Withers DA, Harvey RC, Faust JB, Melnyk O, Carey K, Meeker TC. Characterization of a candidate bcl-1 gene. Mol Cell Biol 1991;11:4846-53.
14. Buckley MF, Sweeney KJ, Hamilton JA, Sini RL, Manning DL, Nicholson RI, et al. Expression and amplification of cyclin genes in human breast cancer. Oncogene 1993;8:2127-33.
15. Fredersdorf S, Burns J, Milne AM, Packham G, Fallis L, Gillett CE, et al. High level expression of p27kipl and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27kip1 and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 1997;94:6380-5.
16. Horenstein MG, Cesarman E, Wang X, Linkov I, Prieto VG, Louie CD. Cyclin D1 and retinoblastoma protein expression in Kaposi's sarcoma. J Cutan Pathol 1997;24:585-9.
17. Sutter T, Doi S, Carnevale KA, Arber N, Weinstein IB. Expression of cyclins D1 and E in human colon adenocarcinomas. J Med 1997;28:285-309.
18. Han EK, Lim JT, Arber N, Rubin MA, Xing WQ, Weinstein IB. Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors. Prostate 1998;35:95-101.
19. Ishikawa T, Furihata M, Ohtsuki Y, Murakami H, Inoue A, Ogoshi S. Cyclin D1 overexpression related to retinoblastoma protein expression as a prognostic marker in human oesophageal squamous cell carcinoma. Br J Cancer 1998;77: 92-7.
20. Marchetti A, Doglioni C, Barbareschi M, Buttitta F, Pellegrini S, Gaeta P, et al. Cyclin D1 and retinoblastoma susceptibility gene alterations in non-small cell lung cancer. Int J Cancer 1998;75:187-92.
21. Jiang W, Kahn SM, Tomita N, Zhang YJ, Lu SH, Weinstein IB. Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Res 1992;52:2980-3.
22. Zukerberg LR, Yang W-I, Gadd M, Thor AD, Koerner FC, Schmidt EV, et al. Cyclin D1 (Prad1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene. Mod Pathol 1995;8:560-7.
23. Berenson JR, Koga H, Yang J, Pearl J, Holmes EC, Figlin R. The lung cancer study group: frequent amplification of the bcl-1 locus in poorly differentiated squamous cell carcinoma of the lung. Oncogene 1991;5:1343-8.
24. Proctor AJ, Coombs LM, Cairns JP, Knowles MA. Amplification at chromosome 11q13 in transitional cell tumors of the bladder. Oncogene 1991;6:789-95.
25. Nakagawa H, Zukerberg L, Togawa K, Meltzer SJ, Nishihara T, Rustoi A. Human cyclin D1 oncogene and esophageal squamous cell carcinoma. Cancer 1995;76:541-9.
26. Michalides R, van Veelen N, Hart A, Loftus B, Wientjens E, Balm A. Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res 1995;55:975-8.
27. Rosai J, Carcangui M, DeLellis R. Tumors of the thyroid gland. In: Rosai J, Sobin L, editors. Atlas of tumor pathology. 3rd series. Fasc. F. Washington, DC: Armed Forces Institute of Pathology; 1992.
28. Berho M, Suster S. The oncocytic variant of papillary carcinoma of the thyroid: a clinicopathologic study of 15 cases. Hum Pathol 1997;28:47-53.
29. Erickson LA, Jin L, Wollan P, Thompson GB, van Heerden JA, Lloyd RV. Parathyroid hyperplasia, adenomas, and carcinomas: differential expression of p27kip1 protein. Am J Surg Pathol 1999;23:288-95.
30. Weiss LM. Comparative histologic study of 43 metastasizing and non-metastasizing adrenocortical tumors. Am J Surg Pathol 1984;8:163-9.
31. van Heerden JA, Hay ID, Goellner JR, Salamao D, Ebersold JR, Bergstralh EJ, et al. Follicular thyroid carcinoma with capsular invasion alone: a non-threatening malignancy. Surgery 1992;112:1130-8.
32. Chen H, Nicol TL, Zeiger MA, Dooley WC, Landenson PW, Cooper DS, et al. Hurthle cell neoplasms of the thyroid: are there factors predictive of malignancy? Ann Surg 1998;227:542-6.
33. Thompson NW, Dunn EL, Batsakis JG, Nishiyama RH. Hurthle cell lesions of the thyroid gland. Surg Gynecol Obstet 1974;139:555-60.
34. Azadian A, Rosen IB, Walfish PG, Asa SL. Management considerations in Hurthle cell carcinoma. Surgery 1995;118:711-5.
35. Carcangiu ML, Bianchi S, Savino D, Voynick IM, Rosai J. Follicular Hurthle cell neoplasms of the thyroid gland: a study of 153 cases. Cancer 1991;68:1944-53.
36. Tallini G, Carcangiu ML, Rosai J. Oncocytic neoplasms of the thyroid gland. Acta Pathologica Japonica 1992;42:305-15.
37. Wang S, Wuu J, Savas J, Patwardhan N, Khan A. The role of cell cycle regulatory proteins, cyclin D1, cyclin E and p27 in thyroid carcinogenesis. Hum Pathol 1998;29:1304-9.